Nisa Investment Advisors
TARA icon

Nisa Investment Advisors’s Protara Therapeutics TARA Stock Holding History

Nisa Investment Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,800
Closed -$25K – 3181
2026
Q1 		$25K Buy
+4,800
New +$28.4K ﹤0.01% 1928

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Nisa Investment Advisors's TARA Position: Q2 2026 in Review

Nisa Investment Advisors sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 4,800 shares — an estimated $25K sold.

Nisa Investment Advisors first reported a position in TARA in Q1 2026 and held it in 1 quarter. The position peaked at $25K in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Nisa Investment Advisors reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nisa Investment Advisors sold 4,800 Protara Therapeutics shares in Q2 2026, an estimated $25K.
  • Nisa Investment Advisors first reported a position in Protara Therapeutics in Q1 2026 and held it in 1 quarter.
  • Nisa Investment Advisors's Protara Therapeutics position peaked at $25K in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.